Bluechiip (ASX:BCT) share price explodes 63% on Fujifilm deal

The company is planning for a big 24 months ahead…

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

The Bluechiip Ltd (ASX: BCT) share price is rocketing to a 3-month high today. This comes after the company announced a lucrative contract with California-based Fujifilm Irvine Scientific, Inc. (FISI).

At the time of writing, Bluechiip shares are surging 63.33% higher to 4.9 cents apiece.

Bluechiip signals strong growth opportunity ahead

Bluechiip develops temperature and tracking solutions for biosamples in the health and life sciences industries. Today, investors are driving up the Bluechiip share price following the company’s latest news to the ASX.

In its statement, Bluechiip advised it has signed a two-year licence and development agreement with FISI.

Founded in 1970, FISI is the world’s leading manufacturer of cell culture media, reagents, and medical devices. These products are used across cell therapy, regenerative medicine, assisted reproductive technology (ART), and industrial cell culture markets.

Under the agreement, FISI will pay Bluechiip to customise and develop a range of technologies for the ART (also known as in-vitro fertilisation, or IVF) market segment. The goal is to improve the traceability of samples and simplify workflows for FISI.

During this initial licence and development period, the companies will work together to agree on a supply agreement for the sale and distribution of the customised Bluechiip products including minimum volumes, pricing, and detailed commercial terms.

Commenting on the news fuelling the Bluechiip share price today, managing director Andrew McLellan said:

Our agreement with FISI will make some contribution to our revenues by way of licence and development fees over the next 18-24 months, but most importantly this agreement provides Bluechiip a solid foothold in a lucrative worldwide market, with a strong international partner.

With more than 2.5 million IVF cycles performed globally each year, the total potential market for a new FISI system incorporating Bluechiip enabled technology is attractive and is expected to result in significant business growth.

About the Bluechiip share price

Over the past 12 months, Bluechiip shares have moved sideways, resulting in a 2% loss for the period. However, its shares have gained around 13% this year to date.

Based on today’s price, Bluechiip has a market capitalisation of roughly $29.3 million, with approximately 597.9 million shares on issue.

Should you invest $1,000 in Bluechiip right now?

Before you consider Bluechiip, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Bluechiip wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Technology Shares